Reflections from the 2026 National Drug Abuse Treatment Clinical Trials Network Annual Meeting
by Manny Alvarez, Postdoctoral Fellow, Center of Alcohol and Substance Use Studies (CAS)
The National Drug Abuse Treatment Clinical Trials Network (CTN) Annual Scientific and Steering Committee Meeting, was held April 13–15, 2026, at the National Institutes of Health (NIH). The meeting brought together researchers, clinicians, and community partners from across the country to share new research and practical strategies for addressing substance use. Alvarez describes the meeting as an opportunity to engage in a national conversation about improving prevention, treatment, and recovery. A key milestone highlighted in his reflection is that CAS has recently joined the CTN through the Greater New York Regional Node. This partnership expands CAS’s role in collaborative, multi-site clinical trials and strengthens its commitment to real-world research that leads to meaningful improvements in care. Drawing on his background in neuroscience, Alvarez reflects on his growing interest in translational research—work that connects scientific discovery with everyday practice. He emphasizes that the CTN model is designed to ensure that evidence-based approaches are not only studied, but also tested and used in real-world clinical and community settings. Across the meeting, Alvarez notes a consistent message: research must better reflect the complexity of people’s lives. Several key themes illustrate how the field is evolving:
- Polysubstance use: Researchers are increasingly studying how people use multiple substances together, rather than focusing on one substance at a time. This shift brings research closer to real-world experience.
- Digital health innovation: New tools, such as smartphones and wearable devices, are being used to track changes in health and substance use in real time, allowing for more personalized and responsive support.
- Emerging treatment approaches: Presentations highlighted ongoing research into medications (such as GLP‑1 receptor agonists) and growing interest in psychedelic-assisted therapies, with attention to safety and clinical application.
- Integrated care: There is strong emphasis on addressing substance use alongside other conditions, including chronic pain, depression, and trauma, to provide more holistic care.
- Cross-sector collaboration: Efforts to connect data across healthcare, housing, and social services are helping researchers better understand recovery in broader life contexts.
- Focus on adolescents: New clinical trials are prioritizing youth, particularly in relation to nicotine and opioid use, to support earlier and more developmentally appropriate interventions.
Alvarez highlights that these developments reflect a broader shift toward research that is more connected, inclusive, and responsive to everyday realities. Innovation in the field is increasingly paired with collaboration—bringing together multiple disciplines, data sources, and community perspectives.
For CAS, participation in the CTN represents an important opportunity to contribute to this evolving landscape. As a new member of the network, CAS is well positioned to engage in national research efforts and help expand the reach of evidence-based care. Alvarez concludes that attending the CTN meeting provided a valuable firsthand view of how addiction science is advancing. He underscores that progress is driven not by a single study or institution, but by collective effort working across research, practice, and community settings to better meet the needs of individuals and communities.